Literature DB >> 17316651

Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population.

Yasuko Miyake1, Rina Kimura2, Yoshihiro Kokubo3, Akira Okayama3, Hitonobu Tomoike4, Taku Yamamura5, Toshiyuki Miyata2.   

Abstract

The aim of this study was to investigate whether plasma low-density lipoprotein cholesterol (LDL-C) levels in the general population are influenced by rare sequence variations in the PCSK9 gene. We sequenced the promoter and coding regions of the PCSK9 gene in individuals from the general population (n=3655) with the lowest (n=78) and highest (n=96) LDL-C levels and in individuals taking antihypercholesterolemia medication (n=96). We identified 33 sequence variants in the PCSK9 gene among which 24 were specific for Japanese. Statistical analysis showed that one missense mutation, R93C, was associated with low LDL-C levels. The other variants had no association with LDL-C levels or the numbers of individuals with the variants were too small for statistical analysis. A comparison of the numbers of individuals with nonsynonymous mutations between the low LDL-C and high LDL-C/treatment groups found that four missense mutations and one nonsense mutation were identified only in the low LDL-C group and six missense mutations were identified only in the high LDL-C/treatment group. As we have analyzed groups at opposite ends of the LDL-C spectrum, it is likely that some of these nonsynonymous mutations may be associated with either low or high LDL-C in the Japanese population. Based on the extremely high frequencies of the nonsynonymous mutations in PCSK9 compared with those of LDLR or apoB-100, PCSK9 mutations could be important factors that cumulatively influence plasma LDL-C levels in the general population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316651     DOI: 10.1016/j.atherosclerosis.2006.12.035

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  24 in total

1.  A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.

Authors:  Angelo B Cefalù; James P Pirruccello; Davide Noto; Stacey Gabriel; Vincenza Valenti; Namrata Gupta; Rossella Spina; Patrizia Tarugi; Sekar Kathiresan; Maurizio R Averna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

2.  Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Authors:  Ali Ben Djoudi Ouadda; Marie-Soleil Gauthier; Delia Susan-Resiga; Emmanuelle Girard; Rachid Essalmani; Miles Black; Jadwiga Marcinkiewicz; Diane Forget; Josée Hamelin; Alexandra Evagelidis; Kevin Ly; Robert Day; Luc Galarneau; Francois Corbin; Benoit Coulombe; Artuela Çaku; Vincent S Tagliabracci; Nabil G Seidah
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-05       Impact factor: 8.311

3.  Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.

Authors:  John S Chorba; Adri M Galvan; Kevan M Shokat
Journal:  J Biol Chem       Date:  2017-12-19       Impact factor: 5.157

4.  Genotyping and Frequency of PCSK9 Variations Among Hypercholesterolemic and Diabetic Subjects.

Authors:  Edem Nuglozeh; Mohammad Feroze Fazaludeen; Nabil Hasona; Tarja Malm; Luisito B Mayor; Awdah Al-Hazmi; Ibraheem Ashankyty
Journal:  Indian J Clin Biochem       Date:  2018-07-30

5.  Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.

Authors:  Fen Du; Yvonne Hui; Michelle Zhang; MacRae F Linton; Sergio Fazio; Daping Fan
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

6.  Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.

Authors:  Quoc-Tuan Le; Matthieu Blanchet; Nabil G Seidah; Patrick Labonté
Journal:  J Biol Chem       Date:  2015-07-20       Impact factor: 5.157

7.  Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure.

Authors:  Khalid Al-Waili; Ward Al-Muna Al-Zidi; Abdul Rahim Al-Abri; Khalid Al-Rasadi; Hilal Ali Al-Sabti; Karna Shah; Abdullah Al-Futaisi; Ibrahim Al-Zakwani; Yajnavalka Banerjee
Journal:  Oman Med J       Date:  2013-01

8.  Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study.

Authors:  Chiang-Ching Huang; Myriam Fornage; Donald M Lloyd-Jones; Gina S Wei; Eric Boerwinkle; Kiang Liu
Journal:  Circ Cardiovasc Genet       Date:  2009-06-10

Review 9.  Lipoproteins, cholesterol homeostasis and cardiac health.

Authors:  Tyler F Daniels; Karen M Killinger; Jennifer J Michal; Raymond W Wright; Zhihua Jiang
Journal:  Int J Biol Sci       Date:  2009-06-29       Impact factor: 6.580

Review 10.  Familial hypercholesterolemia in Southeast and East Asia.

Authors:  Candace L Jackson; Magdi Zordok; Iftikhar J Kullo
Journal:  Am J Prev Cardiol       Date:  2021-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.